Responsraten for topotecan i det kombinerede program for småcellet lungecancer [n = 480] for patienter med recidiverende sygdom efter førstebehandling var 20, 2%.
The response rate to topotecan in the combined small cell lung cancer programme [n = 480] for patients with relapsed disease sensitive to first-line therapy, was 20.2%.